Leidos Biomedical Research, Inc.
Frederick National Laboratory for Cancer Research
Frederick, MD 21702-1201
Jacob D. Estes, Ph.D., is a Principal Scientist/Principal Investigator in the AIDS and Cancer Virus Program (ACVP) at the Frederick National Laboratory for Cancer Research operated by Leidos Biomedical Research, Inc., and currently heads both the Retroviral Immunopathology Section and Tissue Analysis Core within the ACVP. Dr. Estes obtained his Ph.D. at Brigham Young in the laboratory of Dr. Gregory Burton studying the contributions of follicular dendritic cells and the germinal center microenvironment to HIV pathogenesis. Dr. Estes continued his work as a postdoctoral fellow in the laboratory of Dr. Ashley Haase in the Department of Microbiology at the University of Minnesota, focusing on the in vivo immunopathogology of lentiviral infections in lymphoid tissues in both human patient cohorts and non-human primate models. Dr. Estes joined the AIDS and Cancer Virus Program in 2007.
The Retroviral Immunopathology Section (RIPS) studies various aspects of lentiviral mucosal transmission and pathogenesis using state-of-the art tissue analysis capabilities (i.e. immunofluorescence, immunohistochemistry, in situ hybridization, quantitative image analysis, laser capture microdissection, etc.) to better understand in vivo the host-viral interactions following mucosal infection and the immunopathologenic mechanisms and processes of disease progression. Dr. Estes' major research aims are focused on: i) understanding and further elucidating the biology, mechanisms and barriers to lentiviral mucosal transmission and viral dissemination in order to better guide preventative strategies; ii) understanding and identifying the establishment, tissue sanctuaries and cellular sources of persistent lentiviral reservoirs utilizing novel NHP and viral systems; and iii) understanding the factors driving systemic immune activation and disease progression to guide adjunctive therapeutic intervention strategies that can be used to ameliorate immune activation and its associated pathologic consequences.
The Tissue Analysis Core (TAC) provides state-of-the art tissue analysis capabilities (i.e. immunofluorescence, immunohistochemistry, in situ hybridization, quantitative image analysis, laser capture microdissection) for ACVP directed studies and in support of intramural and extramural investigators working on collaborative studies relevant to key questions in HIV/AIDS research, with an emphasis on analysis of specimens from non-human primate (NHP) models. The Tissue Analysis Core is working with ACVP investigators and a network of collaborators to better understand HIV/SIV mucosal transmission, reservoir biology, pathogenesis and therapeutic intervention strategies. To accomplish the diverse array of collaborative studies, the Tissue Analysis Core has invested extensive time and resources to develop and optimize novel next-generation, highly sensitive in situ hybridization strategies for detection of lentiviruses in fixed tissue samples. In addition, Tissue Analysis Core has partnered with the Pathology and Histotechnology Laboratory (PHL) at the FNLCR to generate, produce and make available innovative lineage specific viral RNA riboprobe reagents for in situ hybridization detection of an array viruses in tissue samples (i.e. HIV-1 clades A, B, C, D and CRF01_AE, SIVmac239 lineage 8, SIVsmE660 lineage1, SIVsmM946 lineage 2, SIVsmFTq lineage 5, SIVsmD215 lineage 6, SIVsmSL92B and SIVagm).